DBV Technologies shares fall 4.5%, among the biggest decliners in the SBF 120
The Châtillon-based biotech falls sharply while the Paris index remains stable. The decline comes a few days after new clinical data presented in the United States, in a regulatory file still under review.
A decline that contrasts with a virtually unchanged Paris market
The stock loses 4.47% to €1.88, while the SBF 120 gains 0.01% and the CAC 40 gains 0.04%. It ranks among the largest declines in the index, behind Eramet, Inventiva and Nanobiotix. This session's decline follows that of Friday, which was already negative, but the stock still holds a gain of 15.77% over one month.
Over three months, it remains down 20.58%. The analyses of the VITESSE study, presented at the ACAAI congress in Phoenix, concerned the severity of allergic reactions under Viaskin Peanut in children aged 4 to 7.
The biotech is listed on two markets: the Nasdaq ADS represents five ordinary shares in Paris, and the Paris-listed share remains eligible for the PEA.
Between its MA20 and MA50, the stock keeps a margin above its support
The price is above the MA20 (€1.84, a gap of +2.12%), but below the MA50 (€1.91, a gap of -1.62%). This position, between the two averages, reflects a rebound that has not yet resumed its medium-term trend. The support at €1.57 remains at a good distance, as does the resistance at €2.13.
On the regulatory front, the company indicated, when publishing its results for the first nine months of 2026 (on October 28, 2026), that it expected an FDA decision in the fourth quarter for the Viaskin Peanut patch in children aged 4 to 7, with a request for priority review. It also flagged a doubt about its going concern and a need for capital beyond the third quarter of 2027.
According to the declarations consulted, net short positions total 3.02% of the share capital, spread across four funds and nearly stable over thirty days (+0.03 points). This level, which exceeds 3%, shows that a modest fraction of the capital remains positioned to the downside, without any notable acceleration.